-
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | HK |
| CurrencyCode | HKD |
| ISIN | KYG1996C1006 |
| PE Ratio | None |
|---|---|
| Target Price | 10.1709 |
| Beta | 0.48 |
| Market Cap | 10B |
| Dividend Yield | None |
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma. The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial for patients with targeting Glypican-3 positive to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). In addition, it is developing CT0590 and CT059X, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma and R/R PCL, as well as KJ-C2114 that are in the pre-clinical stage for the treatment of solid tumors; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence. It has collaborated with Moderna, Inc. to investigate satricabtagene autoleucel in combination with Moderna's investigational Claudin18.2 mRNA product.; and East China University of Science and Technology (ECUST) to leverage synergies between academic and industrial resources. The company was founded in 2014 and is headquartered in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2171.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025